Danaher Corporation $DHR Holdings Lowered by Norris Perne & French LLP MI

Key Points

• Norris Perne & French LLP MI has reduced its stake in Danaher Corporation by 34.2%, selling 45,310 shares and resulting in ownership of 87,110 shares valued at approximately $17.21 million.
• Danaher Corporation reported a quarterly EPS of $1.80, surpassing analysts' expectations of $1.64, with a revenue of $5.94 billion, reflecting a 3.4% year-over-year increase.
• The company announced a quarterly dividend of $0.32 per share, which will be paid on October 31st, indicating a dividend yield of 0.7%.

Norris Perne & French LLP MI trimmed its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 34.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 87,110 shares of the conglomerate's stock after selling 45,310 shares during the period. Norris Perne & French LLP MI's holdings in Danaher were worth $17,208,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. GHP Investment Advisors Inc. lifted its holdings in shares of Danaher by 396.0% during the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after purchasing an additional 99 shares during the last quarter. Sierra Ocean LLC lifted its stake in Danaher by 116.9% in the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock worth $29,000 after acquiring an additional 76 shares in the last quarter. Smallwood Wealth Investment Management LLC purchased a new stake in Danaher in the 1st quarter worth about $31,000. Dunhill Financial LLC lifted its stake in Danaher by 68.4% in the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock worth $34,000 after acquiring an additional 67 shares in the last quarter. Finally, Costello Asset Management INC purchased a new stake in Danaher in the 1st quarter worth about $41,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Price Performance

Shares of DHR stock opened at $184.97 on Monday. The stock has a 50 day moving average of $199.44 and a two-hundred day moving average of $197.48. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $279.59. The company has a market capitalization of $132.45 billion, a P/E ratio of 39.36, a P/E/G ratio of 2.63 and a beta of 0.75.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. During the same quarter last year, the company earned $1.72 EPS. The company's quarterly revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a $0.32 dividend. The ex-dividend date is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.7%. Danaher's dividend payout ratio (DPR) is currently 27.23%.

Insider Activity at Danaher

In other Danaher news, Director Teri List sold 2,778 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 11.20% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Wells Fargo & Company reduced their price objective on Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 23rd. Bank of America reduced their price objective on Danaher from $230.00 to $220.00 and set a "buy" rating for the company in a research note on Monday, September 22nd. Royal Bank Of Canada set a $241.00 price objective on Danaher in a research note on Tuesday, September 2nd. Guggenheim reissued a "buy" rating and issued a $250.00 price objective on shares of Danaher in a research note on Wednesday, July 23rd. Finally, Robert W. Baird raised their price target on Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a research note on Friday, July 18th. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $245.91.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.